These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26264631)

  • 41. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children.
    Asturias EJ; Contreras-Roldan IL; Ram M; Garcia-Melgar AJ; Morales-Oquendo V; Hartman K; Rauscher M; Moulton LH; Halsey NA
    Vaccine; 2013 Dec; 31(49):5909-14. PubMed ID: 24055354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of adverse events following pentavalent and diphtheria-tetanus-pertussis vaccines among Nigerian children.
    Sadoh AE; Nwaneri DU; Ogboghodo BC; Sadoh WE
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):119-122. PubMed ID: 28585776
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does concomitant injection of a combined diphtheria-tetanus-acellular pertussis - hepatitis B virus - inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines?
    Usonis V; Bakasenas V
    Eur J Pediatr; 1999 May; 158(5):398-402. PubMed ID: 10333123
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran.
    Karami M; Ameri P; Bathaei J; Berangi Z; Pashaei T; Zahiri A; Zahraei SM; Erfani H; Ponnet K
    BMC Immunol; 2017 Aug; 18(1):42. PubMed ID: 28835207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
    Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.
    Sharma HJ; Yadav S; Lalwani SK; Kapre SV; Jadhav SS; Chakravarty A; Parekh SS; Palkar S; Bhardwaj SH; Namjoshi GS; Verma V
    Hum Vaccin; 2011 Apr; 7(4):451-7. PubMed ID: 21403463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine.
    Dutta AK; Verghese VP; Pemde HK; Mathew LG; Ortiz E
    Indian Pediatr; 2009 Nov; 46(11):975-82. PubMed ID: 19955579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How did the adoption of wP-pentavalent affect the global paediatric vaccine coverage rate? A multicountry panel data analysis.
    Khan MM; Vargas-Zambrano JC; Coudeville L
    BMJ Open; 2022 Apr; 12(4):e053236. PubMed ID: 35379619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority study.
    Capeding MR; Alberto E; Versteilen A; Rauscher M; Bagchi P; Palacios PI
    Int J Infect Dis; 2016 May; 46():71-8. PubMed ID: 26923083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority study.
    Capeding MR; Jica C; Macura-Biegun A; Rauscher M; Alberto E
    Vaccine; 2014 Feb; 32(7):888-94. PubMed ID: 24176498
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia.
    Griffiths UK; Korczak VS; Ayalew D; Yigzaw A
    Vaccine; 2009 Feb; 27(9):1426-32. PubMed ID: 19146901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary vaccination with a new heptavalent DTPw-HBV/Hib-Neisseria meningitidis serogroups A and C combined vaccine is well tolerated.
    Kerdpanich A; Warachit B; Kosuwon P; Gatchalian SR; Watanaveeradej V; Borkird T; Kosalaraksa P; Han HH; Hutagalung Y; Boutriau D; Dobbelaere K
    Int J Infect Dis; 2008 Jan; 12(1):88-97. PubMed ID: 17716936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
    Avdicová M; Prikazský V; Hudecková H; Schuerman L; Willems P
    Eur J Pediatr; 2002 Nov; 161(11):581-7. PubMed ID: 12424582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.
    Eregowda A; Lalwani S; Chatterjee S; Vakil H; Ahmed K; Costantini M; Lattanzi M
    Hum Vaccin Immunother; 2013 Sep; 9(9):1903-9. PubMed ID: 23783081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of a multinational, multilingual vaccine debate on Twitter.
    Becker BF; Larson HJ; Bonhoeffer J; van Mulligen EM; Kors JA; Sturkenboom MC
    Vaccine; 2016 Dec; 34(50):6166-6171. PubMed ID: 27840012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study.
    Monge S; Hahné SJ; de Melker HE; Sanders EA; van der Ende A; Knol MJ
    Lancet Infect Dis; 2018 Jul; 18(7):749-757. PubMed ID: 29752131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants.
    Pichichero ME; Latiolais T; Bernstein DI; Hosbach P; Christian E; Vidor E; Meschievitz C; Daum RS
    Pediatr Infect Dis J; 1997 Sep; 16(9):863-70. PubMed ID: 9306481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.